The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Comparison of Combined Bupropion and Naltrexone Therapy for Obesity with Monotherapy and Placebo
Abstract
CONTEXT: The efficacy of current centrally acting obesity pharmacotherapies is limited by compensatory mechanisms that mitigate weight loss. OBJECTIVE: Our objective was to determine whether opioid receptor antagonism (naltrexone) plus pro-opiomelanocortin activation (bupropion) causes greater weight loss than placebo or monotherapy. DESIGN/SETTING: A randomized, placebo- and monotherapy-controlled, double-blind, dose-finding trial was conducted from August 2005 to December 2006 in seven U.S. outpatient clinics. PARTICIPANTS: A total of 419 patients with uncomplicated obesity participated. INTERVENTIONS: Interventions included 24 wk of sustained-release bupropion (400 mg/d), immediate-release naltrexone (48 mg/d), placebo, and three combination therapy [naltrexone/bupropion (NB)] groups consisting of immediate-release naltrexone, 16, 32, or 48 mg/d, plus sustained-release bupropion (400 mg/d) with a 24-wk extension. A minimal diet and exercise component was also included. MAIN OUTCOME MEASURES: Percent weight change from baseline at wk 24 in the intent-to-treat population for NB48 vs. placebo and monotherapy was assessed. Other measurements included body mass index, waist circumference, fasting lipids, glycemic variables, safety, and tolerability. RESULTS: At wk 24, placebo-subtracted weight loss was -4.62% [95% confidence interval (CI) -6.24 to -2.99; P < 0.001] for NB16, -4.65% (95% CI -6.20 to -3.09; P < 0.001) for NB32, and -3.53% (95% CI -5.15 to -1.90; P < 0.001) for NB48. Weight loss was statistically significant vs. monotherapy for all three NB combinations with the exception of NB48 vs. bupropion. Weight loss with NB continued after wk 24. The most common treatment-emergent adverse event was mild transient nausea. CONCLUSIONS: NB caused gradual sustained weight loss over 48 wk; NB32 and NB16 demonstrated greater weight loss in the intent-to-treat population due to lower attrition rates. Further study is needed to demonstrate long-term efficacy and safety of NB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Secondary analyses show the benefits of binge frequency and global impressions of severity [139].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [139]
Experimental — accuracy not yet measuredIn the citing paper
“Highly-effective AOMs, including nutrient-stimulated hormone-based therapies, induce mean weight loss of 15% or more.”
From Approach to Obesity Treatment in Primary Care: A Review (2024) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
Excess Deaths Associated With Underweight, Overweight, and Obesity
Flegal, K. M. (2005) · JAMA · doi:10.1001/jama.293.15.1861 · Cited by 2,811
Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects
(2014) · Jahrbuch für Wissenschaft und Ethik · doi:10.1515/jwiet-2014-0117 · Cited by 2,483
Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus
Cowley, M. A., Smart, J. L., Rubinstein, M., Cerdán, M. G., Diano, S., Horvath, T. L., Cone, R. D., & Low, M. J. (2001) · Nature · doi:10.1038/35078085 · Cited by 2,356
Self-citationWang, G.-J., Volkow, N. D., Logan, J., Pappas, N. R., Wong, C. T., Zhu, W., Netusll, N., & Fowler, J. S. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03643-6 · Cited by 1,864
Anatomy and regulation of the central melanocortin system
Cone, R. D. (2005) · Nature Neuroscience · doi:10.1038/nn1455 · Cited by 1,583
The Neuroscience of Natural Rewards: Relevance to Addictive Drugs
Kelley, A. E., & Berridge, K. C. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03306.2002 · Cited by 1,505
Association between obesity and psychiatric disorders in the US adult population
Simon, G. E., Von Korff, M., Saunders, K., Miglioretti, D. L., Crane, P. K., van Belle, G., & Kessler, R. C. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.824 · Cited by 1,338
How can drug addiction help us understand obesity?
Volkow, N. D., & Wise, R. A. (2005) · Nature Neuroscience · doi:10.1038/nn1452 · Cited by 1,089
Mykletun, A., Stordal, E., & Dahl, A. A. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.6.540 · Cited by 908
Research works printed but not linked: 1
- 2001, The Surgeon General’s call to action to prevent and decrease overweight and obesity
Cited by
Sorted by citations
Long-term persistence of hormonal adaptations to weight loss
Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105816 · Cited by 1,449
Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60888-4 · Cited by 1,036
Self-citationApovian, C. M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., Kim, D., Dunayevich, E., & for the COR‐II Study Group (2013) · Obesity · doi:10.1002/oby.20309 · Cited by 720
Self-citationTirzepatide as Compared with Semaglutide for the Treatment of Obesity
Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2416394 · Cited by 634
Wadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi‐Sunyer, F. X., Rock, C. L., Erickson, J. S., et al. (2011) · Obesity · doi:10.1038/oby.2010.147 · Cited by 558
Self-citationDeal, C., Tony, M., Höybye, C., Allen, D. B., Tauber, M., & Christiansen, J. S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3888 · Cited by 380
Shariq, O. A., & McKenzie, T. J. (2020) · Gland Surgery · doi:10.21037/gs.2019.12.03 · Cited by 427
Review article: the role of gastric motility in the control of food intake
Janssen, P., Berghe, P. V., Verschueren, S., Lehmann, A., Depoortere, I., & Tack, J. F. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04609.x · Cited by 360
The defence of body weight: a physiological basis for weight regain after weight loss
Sumithran, P., & Proietto, J. (2013) · Clinical Science · doi:10.1042/cs20120223 · Cited by 310
Pharmacotherapies for Obesity: Past, Current, and Future Therapies
Ioannides‐Demos, L. L., Piccenna, L. G., & McNeil, J. J. (2010) · Journal of Obesity · doi:10.1155/2011/179674 · Cited by 241
Phentermine and topiramate for the management of obesity: a review
Uwaifo, G. I., Cosentino, & Conrad, A. O. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s31443 · Cited by 242
Effect of combined naltrexone and bupropion therapy on the brain’s reactivity to food cues
Wang, G.-J., Tomasi, D. G., Volkow, N. D., Wang, R., Telang, F., Caparelli, E. C., & Dunayevich, E. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.145 · Cited by 242
Self-citationNaltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss
Billes, S. K., Sinnayah, P., & Cowley, M. A. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.04.004 · Cited by 255
Self-citationCaixàs, A., Albert, L., Capel, I., & Rigla, M. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s55587 · Cited by 236
Neural Control of Energy Balance: Translating Circuits to Therapies
Gautron, L., Elmquist, J. K., & Williams, K. W. (2015) · Cell · doi:10.1016/j.cell.2015.02.023 · Cited by 250
Diets and drugs for weight loss and health in obesity – An update
Aaseth, J., Ellefsen, S., Alehagen, U., Sundfør, T. M., & Alexander, J. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111789 · Cited by 180
New Drug Targets for the Treatment of Obesity
Powell, A. G., Apovian, C. M., & Aronne, L. J. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.82 · Cited by 160
Centrally Acting Agents for Obesity: Past, Present, and Future
Coulter, A. A., Rebello, C. J., & Greenway, F. L. (2018) · Drugs · doi:10.1007/s40265-018-0946-y · Cited by 151
Self-citationBehavioral and pharmacologic therapies for obesity
Vetter, M. L., Faulconbridge, L. F., Webb, V. L., & Wadden, T. A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.121 · Cited by 124
The relationship between opioid and sugar intake: Review of evidence and clinical applications
Mysels, D. J., & Sullivan, M. A. (2011) · Journal of Opioid Management · doi:10.5055/jom.2010.0043 · Cited by 122
Central control of thermogenesis
Clapham, J. C. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.10.014 · Cited by 128
Long-term effects of weight-reducing drugs in people with hypertension
Siebenhofer, A., Jeitler, K., Horvath, K., Berghold, A., Posch, N. A. S., Meschik, J., & Semlitsch, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub4 · Cited by 118
Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs
Nathan, P. J., O’Neill, B. V., Napolitano, A., & Bullmore, E. T. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00172.x · Cited by 115
The overlap between binge eating disorder and substance use disorders: Diagnosis and neurobiology
Schreiber, L. R. N., Odlaug, B. L., & Grant, J. E. (2013) · Journal of Behavioral Addictions · doi:10.1556/jba.2.2013.015 · Cited by 120
Mechanisms underlying current and future anti-obesity drugs
Adan, R. A. H. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2012.12.001 · Cited by 108
Ulrich‐Lai, Y. M., & Ryan, K. K. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.020 · Cited by 113
Approach to Obesity Treatment in Primary Care: A Review
Yanovski, S. Z., & Yanovski, J. A. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.8526 · Cited by 103
Update on Treatment Strategies for Obesity
Wyatt, H. R. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3115 · Cited by 104
Grilo, C. M., Lydecker, J. A., Fineberg, S. K., Moreno, J. O., Ivezaj, V., & Gueorguieva, R. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220267 · Cited by 89
Boswell, R. G., Potenza, M. N., & Grilo, C. M. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.10.014 · Cited by 89
Current and emerging medications for overweight or obesity in people with comorbidities
Fujioka, K. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12502 · Cited by 76
Self-citationPharmacological management of binge eating disorder: current and emerging treatment options
McElroy, S., Guerdjikova, A. I., Mori, N., & O’Melia, A. (2012) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s25574 · Cited by 74
Kennett, G. A., & Clifton, P. G. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.07.020 · Cited by 77
Pharmacologic Therapies for Obesity
Kaplan, L. M. (2010) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2010.01.001 · Cited by 73
Combination therapy with naltrexone and bupropion for obesity
Billes, S. K., & Greenway, F. L. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.591382 · Cited by 74
Self-citationLong-term effects of weight-reducing drugs in people with hypertension
Siebenhofer, A., Winterholer, S., Jeitler, K., Horvath, K., Berghold, A., Krenn, C., & Semlitsch, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub5 · Cited by 70
Rosenblit, P. D. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0412-7 · Cited by 67
The limits and challenges of antiobesity pharmacotherapy
Gadde, K. M., & Atkins, K. D. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1748599 · Cited by 65
Managing the side effects associated with commonly used treatments for bipolar depression
Kemp, D. E. (2014) · Journal of Affective Disorders · doi:10.1016/s0165-0327(14)70007-2 · Cited by 68
Wilcox, C. S., Oskooilar, N., Erickson, J., Billes, S. K., Katz, B. B., Tollefson, G. D., & Dunayevich, E. (2009) · Addictive Behaviors · doi:10.1016/j.addbeh.2009.10.017 · Cited by 61
Self-citationGrilo, C. M., Lydecker, J. A., Morgan, P. T., & Gueorguieva, R. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.10.010 · Cited by 59
New pharmacological approaches for obesity management
Rueda‐Clausen, C. F., Padwal, R. S., & Sharma, A. M. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.113 · Cited by 57
Pharmacotherapy for Patients with Obesity
Gadde, K. M., Apolzan, J. W., & Berthoud, H. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.272815 · Cited by 57
Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity
Smith, S. R., Fujioka, K., Gupta, A. K., Billes, S. K., Burns, C., Kim, D., Dunayevich, E., & Greenway, F. L. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12095 · Cited by 55
Self-citationHypertension in Obesity: Novel Insights
Natsis, M., Antza, C., Doundoulakis, I., Stabouli, S., & Kotsis, V. (2019) · Current Hypertension Reviews · doi:10.2174/1573402115666190415154603 · Cited by 60
Carbone, E. A., Caroleo, M., Rania, M., Calabrò, G., Staltari, F. A., de Filippis, R., Aloi, M., Condoleo, F., Arturi, F., & Segura-Garcia, C. (2021) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-020-00910-x · Cited by 52
Naltrexone ER/Bupropion ER: A Review in Obesity Management
Greig, S. L., & Keating, G. M. (2015) · Drugs · doi:10.1007/s40265-015-0427-5 · Cited by 50
Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice
Gadde, K. M., & Raj, Y. P. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0859-2 · Cited by 49
Khodaei, F., Rashedinia, M., Heidari, R., Rezaei, M., & Khoshnoud, M. J. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116954 · Cited by 45
Pharmacotherapy in pediatric obesity: current evidence and landscape
Singhal, V., Sella, A. C., & Malhotra, S. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000587 · Cited by 51
Koncz, D., Tóth, B., Roza, O., & Csupor, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.611361 · Cited by 46
Boughton, C. K., & Murphy, K. G. (2012) · British Journal of Pharmacology · doi:10.1111/bph.12037 · Cited by 45
Obesity and diabetes mellitus in the Arab world
Alzaman, N. S., & Ali, A. (2016) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2016.03.009 · Cited by 43
Opioid analgesics and narcotic antagonists
Ghodse, A. H., & Galea, S. (2012) · Side effects of drugs annual · doi:10.1016/b978-0-444-59499-0.00008-8 · Cited by 42
Hypothalamic opioid–Melanocortin appetitive balance and addictive craving
Reece, A. S. (2010) · Medical Hypotheses · doi:10.1016/j.mehy.2010.09.002 · Cited by 40
McElroy, S. L., Guerdjikova, A. I., Kim, D. D. H., Burns, C. M., Harris-Collazo, R., Landbloom, R. P., & Dunayevich, E. (2013) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.12m01494 · Cited by 40
Self-citationNaltrexone SR/Bupropion SR (Contrave): A New Approach to Weight Loss in Obese Adults.
Ornellas, T., & Chavez, B. (2011) · PubMed Central · Cited by 39
Tek, C., Ratliff, J. C., Reutenauer, E. L., Ganguli, R., & O'Malley, S. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000192 · Cited by 39
Combination Drugs for Treating Obesity
Greenway, F. L., & Bray, G. A. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0096-4 · Cited by 38
Self-citationSumińska, M., Podgórski, R., Bogusz‐Górna, K., Skowrońska, B., Mazur, A., & Fichna, M. (2022) · Obesity Reviews · doi:10.1111/obr.13440 · Cited by 39
Christou, G. A., & Kiortsis, D. N. (2015) · HORMONES · doi:10.14310/horm.2002.1600 · Cited by 37
Bischoff, S. C., & Schweinlin, A. (2020) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2020.04.013 · Cited by 44
Combinations of drugs in the Treatment of Obesity
Halpern, B., Oliveira, E. S. L., Faria, A. M., Halpern, A., de Melo, M. E., Cercato, C., & Mancini, M. C. (2010) · Pharmaceuticals · doi:10.3390/ph3082398 · Cited by 36
Naltrexone/Bupropion: An Investigational Combination for Weight Loss and Maintenance
Makowski, C. T., Gwinn, K. M., & Hurren, K. M. (2011) · Obesity Facts · doi:10.1159/000335352 · Cited by 37
Pi-Sunyer, X., Apovian, C. M., McElroy, S. L., Dunayevich, E., Acevedo, L. M., & Greenway, F. L. (2019) · International Journal of Obesity · doi:10.1038/s41366-018-0302-z · Cited by 36
Self-citationTek, C. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s84778 · Cited by 38
Neuropharmacology of compulsive eating
Moore, C. F., Panciera, J. I., Sabino, V., & Cottone, P. (2018) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2017.0024 · Cited by 34
Recent advances in the pathophysiology and pharmacological treatment of obesity
Chugh, P. K., & Sharma, S. (2012) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2012.01347.x · Cited by 33
Targeting nicotine addiction: the possibility of a therapeutic vaccine
Escobar‐Chávez, J. J. (2011) · Drug Design Development and Therapy · doi:10.2147/dddt.s10033 · Cited by 35
Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents
Samson, S. L., & Garber, A. J. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.005 · Cited by 37
Cunningham, J. I., Eyerman, D. J., Todtenkopf, M. S., Dean, R. L., Deaver, D. R., Sánchez, C., & Namchuk, M. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119856850 · Cited by 33
Olney, J. J., Navarro, M., & Thiele, T. E. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00128 · Cited by 33
Cardiovascular Effects of the New Weight Loss Agents
Vorsanger, M., Subramanyam, P., WEINTRAUB, H. S., Lamm, S. H., Underberg, J. A., Gianos, E., Goldberg, I. J., & Schwartzbard, A. Z. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.007 · Cited by 33
Stimulants for the Control of Hedonic Appetite
Poulton, A. S., Hibbert, E., Champion, B. L., & Nanan, R. K. H. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00105 · Cited by 31
Burnham, N. W., Chaimowitz, C., Vis, C. C., Dornellas, A. P. S., Navarro, M., & Thiele, T. E. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108702 · Cited by 28
Clapper, J. R., Athanacio, J., Wittmer, C., Griffin, P. S., D’Souza, L. J., Parkes, D. G., & Roth, J. D. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.11.010 · Cited by 29
Feingold, K. R. (2015) · Europe PMC (PubMed Central) · Cited by 28
Grilo, C. M., Lydecker, J. A., & Gueorguieva, R. V. (2023) · Psychological Medicine · doi:10.1017/s0033291723001800 · Cited by 27
Mason, A. E., Laraia, B. A., Daubenmier, J. J., Hecht, F. M., Lustig, R. H., Puterman, E. M., Adler, N., Dallman, M. F., Kiernan, M., Gearhardt, A. N., et al. (2015) · Eating Behaviors · doi:10.1016/j.eatbeh.2015.06.008 · Cited by 29
Katsiki, N., Hatzitolios, A. I., & Mikhailidis, D. P. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.541490 · Cited by 27
Tuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02700-7 · Cited by 29
Epidemiology of Obesity and Pharmacologic Treatment Options
Shettar, V., Patel, S., & Kidambi, S. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533617713189 · Cited by 26
Treating morbid obesity in cirrhosis: A quest of holy grail
Kumar, N. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i28.2819 · Cited by 25
Emerging pharmacotherapy for obesity
Aronne, L. J., Powell, A. G., & Apovian, C. M. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.609168 · Cited by 26
Jindal, A., Brietzke, S., & Sowers, J. R. (2012) · Cardiorenal Medicine · doi:10.1159/000343803 · Cited by 25
Fortin, J., Ci, L., Schroeder, J., Goldstein, C., Montefusco, M. C., Peter, I., Reís, S. E., Huggins, G. S., Beinborn, M., & Kopin, A. S. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064188 · Cited by 25
Effect of combined naltrexone and bupropion therapy on the brain’s functional connectivity
Wang, G., Zhao, J., Tomasi, D. G., Kojori, E. S., Wang, R., Wiers, C. E., Caparelli, E. C., & Volkow, N. D. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0040-2 · Cited by 25
Byanyima, J. I., Li, X., Vesslee, S. A., Kranzler, H. R., Shi, Z., & Wiers, C. E. (2023) · Current Addiction Reports · doi:10.1007/s40429-023-00493-4 · Cited by 21
Sustained-release Naltrexone/Bupropion— A Novel Pharmacologic Approach to Obesity and Food Craving
Fujioka, K. (2014) · US Endocrinology · doi:10.17925/use.2014.10.01.53 · Cited by 22
Self-citationLiu, Y., Han, F., Xia, Z., Sun, P., Rohani, P., Amirthalingam, P., & Sohouli, M. H. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01319-7 · Cited by 23
Bray, G. A. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20207 · Cited by 22
Neuropeptide receptors as potential pharmacological targets for obesity
Meneguetti, B. T., Cardoso, M. H. E. S., Ribeiro, C. F. A., Felício, M. R., Pinto, I. B., Santos, N. C., Carvalho, C. M. E., & Franco, O. L. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.002 · Cited by 23
Tek, C., Gülöksüz, S., Srihari, V. H., & Reutenauer, E. L. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-176 · Cited by 21
A Comparison of New Pharmacological Agents for the Treatment of Obesity
Nuffer, W. A., Trujillo, J. M., & Megyeri, J. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016634351 · Cited by 22
Psychological Co-morbidities of Obesity
Pagoto, S., Schneider, K. L., Appelhans, B. M., Curtin, C., & Hajduk, A. M. (2011) · Springer eBooks · doi:10.1007/978-1-4419-0029-6_1 · Cited by 21
Navarro, M., Luhn, K. L., Kampov‐Polevoy, A. B., Garbutt, J. C., & Thiele, T. E. (2019) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13992 · Cited by 20
Navarro, M., Carvajal, F., Lerma-Cabrera, J. M., Cubero, I., Picker, M. J., & Thiele, T. E. (2015) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12774 · Cited by 19
Reuptake Inhibitors of Dopamine, Noradrenaline, and Serotonin
Kintscher, U. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-24716-3_15 · Cited by 19
Safety and efficacy of naltrexone for weight loss in adult patients – a systematic review
Kułak-Bejda, A., Bejda, G., & Waszkiewicz, N. (2020) · Archives of Medical Science · doi:10.5114/aoms.2020.96908 · Cited by 18
McMahan, V., Kingston, S., Newman, A., Stekler, J. D., Glick, S. N., & Banta‐Green, C. J. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108243 · Cited by 18
Metadata
- Authors
- Greenway, F. L., Dunayevich, E., Tollefson, G., Erickson, J., Guttadauria, M., Fujioka, K., Cowley, M. A., & for the NB-201 Study Group
- Affiliations
- Pennington Biomedical Research Center (US)
- Orexigen Therapeutics (United States) (US)
- Indiana University School of Medicine (US)
- MG Consulting, Inc. (M.G.), New York, New York 10462
- Scripps Health (US)
- Corresponding author
- Greenway, Frank L.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2009-12-01
- Volume
- 94
- Issue
- 12
- Pages
- 4898-4906
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2036089668
- Cited by
- 179
- References
- 24
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 7 · 2023: 4 · 2022: 5 · 2021: 9 · 2020: 11 · 2019: 10 · 2018: 8 · 2017: 9 · 2016: 13 · 2015: 17 · 2014: 12 · 2013: 14 · 2012: 10
- FWCI
- 10.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Louisiana State University
- Orexigen Therapeutics
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- obesity, bupropion, naltrexone, combination pharmacotherapy, weight loss, opioid antagonism, proopiomelanocortin, sustained weight loss, dose-finding, nausea, fasting lipids, glycemic control, waist circumference, body mass index, diet and exercise, treatment discontinuation, drug safety and tolerability
- MeSH terms
- Adolescent, Adult, Appetite, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Naltrexone, Narcotic Antagonists, Obesity, Risk Factors, Cohort Studies, Weight Loss, Bupropion, Dopamine Uptake Inhibitors, Endpoint Determination, Positron-Emission Tomography, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
